Table 2 Demographic data cases 6–9
Parameter | Case 6 | Case 7 | Case 8 | Case 9 |
|---|---|---|---|---|
Age (years) | 14 | 18 | 5 | 4 |
Gender | Male | Male | Male | Male |
Clinical | Melena stools, fatigue | Leucocytosis, anaemia, thrombocytopenia no organomegaly | Generalized ecchymosis, bruises, epistaxis and hepatomegaly | Fever, malaise failure to thrive |
WBC (109/L) | 16.5 | 33 | 16.1 | 100 |
HB (g/dl) | 10.1 | 8.2 | 6.7 | 7.8 |
PLT (X109/L) | 20 | 67 | 14 | 101 |
PB blasts | 30% | 70% | 40% | 70% |
Bone marrow aspirate | 90% blasts with AML MO morphology | 70% blasts | 40% blasts With dysplasia | 90% blasts comprised of two distinct populations |
Blasts | 90% | 70% | 40% | 90% |
Disease | AML MO | AML M2 | AML M7 | B/MYELOID |
Cytogenetic analysis (karyotype/FISH) | 46,XY,t(7;14) (q22;q32) | 46,XY,t(11;20) (p15;q11), add(21)(p11) | t(12;17)(q15;q23), del(7)(p15), inv. (8)(q22q24) with(2+) and(19+) | 46,XY,der(15)t(1;15) (q10;q10),der(17) t(17;19)(q21;p13.3) |
Chemotherapy | Received induction (3 + 7) for AML then high risk MAC/G protocol | AML induction chemotherapy (3 + 7) protocol. Allogeneic stem cell transplant with steroid refractory graft vs host disease treated with ATG | MRC AML12 Protocol | Received 7 chemotherapy cycles |
Survival | Refractory disease and demised secondary to chemotherapy side effects | Complete remission | Patient demised | Not attain remission Status. Relapsed for MUD transplant |